Evidence map›Paper›PMID 39940144›Full record

ReviewNanomaterials (Basel, Switzerland)2025

A Review of the Carcinogenic Potential of Thick Rigid and Thin Flexible Multi-Walled Carbon Nanotubes in the Lung.

Omnia Hosny Mohamed Ahmed, Aya Naiki-Ito, Satoru Takahashi, William T Alexander, David B Alexander, Hiroyuki Tsuda

Abstract readReview
In one paragraph

Review in Nanomaterials (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Omnia Hosny Mohamed AhmedNanotoxicology Project, Nagoya City University, Nagoya 467-8603, Japan.ORCID 0000-0001-5241-2195
Aya Naiki-ItoDepartment of Experimental Pathology and Tumor Biology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan.ORCID 0000-0003-0828-2033
Satoru TakahashiDepartment of Experimental Pathology and Tumor Biology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan.ORCID 0000-0002-8139-8158
William T AlexanderNanotoxicology Project, Nagoya City University, Nagoya 467-8603, Japan.
David B AlexanderNanotoxicology Project, Nagoya City University, Nagoya 467-8603, Japan.ORCID 0000-0002-9017-3639
Hiroyuki TsudaNanotoxicology Project, Nagoya City University, Nagoya 467-8603, Japan.ORCID 0000-0001-7992-6217

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The carcinogenic potential of MWCNTs is not well defined. Currently, IARC has classified MWCNT-7 as a Group 2 B material, possibly carcinogenic to humans, and all other MWCNTs as Group 3 materials, inadequate evidence in experimental animals for their carcinogenicity and not classifiable as to their carcinogenicity to humans. In this review we discuss studies that investigated the lung toxicity of well characterized MWCNTs in mice and rats. Intraperitoneal and intrascrotal injection studies identified rigid MWCNTs as hazardous materials. The assessment of lung toxicity of MWCNTs in short and medium term instillation and inhalation studies were not conclusive; therefore, these studies do not confirm the hazard of MWCNTs. However, two-year carcinogenicity studies indicate that MWCNT-7 and other MWCNTs, both thick rigid MWCNTs and thin flexible MWCNTs, are carcinogenic in test animals. Therefore, the carcinogenicity of MWCNTs in experimental animals should be reassessed.

Indexed as

classification of MWCNTs by IARCmulti-walled carbon nanotubestoxicity and carcinogenicity of MWCNTs

Identifiers

PMID39940144
PMCPMC11820818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.